FDA Issues Draft Guidance on Patient Counseling Info for Labeling - - BioPharm International

ADVERTISEMENT

FDA Issues Draft Guidance on Patient Counseling Info for Labeling


FDA has released its draft guidance, Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products—Content and Format. The document gives guidance on the development of patient counseling information on labels has required under § 201.57(c)(18) (21 CFR 201.57(c)(18)). The guidance is intended to assist applicants with deciding what topics to include in a label’s patient counseling information section as well as the presentation and organization of those topics.

A final rule amending requirements for the content and formatting of labeling, published on Jan. 24, 2006, created the new required section, Patient Counseling Information (§ 201.57(c)(18)). The section summarizes the information that a healthcare provider should convey to a patient. According to the draft guidance, patient-counseling information must contain information necessary for patients to use the drug safely and effectively and, if applicable, reference to FDA-approved patient labeling.

Source: FDA.gov

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Lundbeck CEO Resigns Due to Code of Conduct Breach
November 24, 2014
IMS: Global Spending on Medicines to Rise 30% by 2018
November 24, 2014
Janssen Partners with Transposagen Biopharmaceuticals for CAR-T Therapies
November 24, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Author Guidelines

Click here